This player's pipeline should keep growth going over the long run.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 5 undervalued ...

Apogee Therapeutics (NASDAQ: APGE) is one of the 17 biotechnology stocks with more than 50% upside. On January 25, Citi analyst Geoff Meacham maintained a Buy rating on Apogee Therapeutics ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one ...

The tenth stock on our list is Legend Biotech Corporation (NASDAQ:LEGN). TheFly reported on January 22 that H.C. Wainwright lowered LEGN’s price target to $50 from $60 but kept a Buy rating, noting Q4 ...

The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, ...

The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns about potential high tariffs initially hurt the industry, sentiment among ...

The drug and biotech sector witnessed a see-saw performance in 2025. After a weak show for most of the year, the sector picked up in the past couple of months. This can be attributed to improved ...